Becton Dickinson Inks Deal With Trump Administration to Invest $19 Billion in U.S. in Exchange for Tariff Relief

By Kelly Cloonan

Becton Dickinson entered an agreement with the Trump administration to expand domestic manufacturing in exchange for relief from future tariffs.

Under the deal, the medical technology company said it would invest $19 billion in the U.S. over several years, including $3 billion toward expanding its U.S. manufacturing.

The company also plans to produce an additional five billion medical consumables in the U.S. annually - which it said would raise its share of domestically supplied essential medical consumables to roughly 80% - and domestically manufacture all of its needles used in the U.S. using American-made steel.

In exchange, Becton Dickinson would get relief from future tariffs imposed on its covered products and inputs. The Franklin Lakes, N.J., company said it is not yet quantifying the financial effect of the agreement because that part of the deal is subject to the final scope and implementation of any future tariff policy changes, as well as its achievement of agreed milestones.

The agreement comes as the Trump administration puts pressure on pharmaceutical and other companies in the medical industry to onshore manufacturing.

President Trump outlined part of the deal with Becton Dickinson in a Monday social media post, and said he would put medical device tariffs in place by the end of the year.

"BUILD IN AMERICA, HIRE AMERICAN WORKERS, AND TREAT AMERICAN PATIENTS FAIRLY - OR PAY!" Trump said in the post.

Trump said Becton Dickinson would ramp up production in Nebraska in particular, with plans to put more than $1 billion of its $3 billion manufacturing investment toward the state.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

October 06, 2026 07:30 ET (11:30 GMT)